Author name: DrugPatentWatch

Part I: The Economic Architecture of Pharmaceutical Intellectual Property 1.1 The Patent Bargain and Its Financial Consequences The pharmaceutical industry […]

For pharma IP teams, portfolio managers, R&D leads, and institutional investors who need a complete, jurisdiction-by-jurisdiction framework — not another

Part I: Why Biologic Patents Are a Different Animal A biologic patent application is not a harder version of a

A deep-dive reference for IP teams, R&D leads, patent counsel, and portfolio managers navigating combination therapy exclusivity Section 1: Executive

The Affordability Paradox: Why Thin Margins Are a Systemic Risk Generic drugs filled 91% of all U.S. prescriptions in 2022,

Part I: Market Architecture and the Valuation Problem Why the Headlines Are Misleading The Latin American generic drug market will

Section 1: What Biosimilar Cost-Effectiveness Actually Measures The Misread Metric Most coverage of biosimilars collapses cost-effectiveness into a single question:

Somewhere in a regulatory affairs department right now, a development team is arguing about whether to run a comparative clinical

There is a certain type of pharmaceutical executive who still thinks of patent searching as something lawyers do—a back-office function